August 27, 2012
Kyowa Hakko Kirin announced on August 23 that it has initiated a PII clinical trial in Europe and the US of its first antibody drug mogamulizumab for the treatment of adult T-cell leukemia-lymphoma (ATL). The trial will run from July...read more